Regenxbio IncNASDAQ:RGNX
- LAST PRICE14.9600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots14.5000/ 4
- Ask / Lots17.0000/ 1
- Open / Previous Close15.1000 / 14.9600
- Day Range
- 52 Week Range
- Volume270,479
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 4309 | 15.1 |
| 09:34 ET | 100 | 15.39 |
| 09:36 ET | 100 | 15.11 |
| 09:38 ET | 231 | 15.21 |
| 09:39 ET | 100 | 15.15 |
| 09:41 ET | 300 | 15.04 |
| 09:43 ET | 774 | 15.01 |
| 09:48 ET | 100 | 14.84 |
| 09:50 ET | 100 | 14.925 |
| 09:52 ET | 100 | 14.94 |
| 09:54 ET | 100 | 14.97 |
| 09:56 ET | 400 | 14.92 |
| 09:57 ET | 300 | 14.98 |
| 09:59 ET | 801 | 14.96 |
| 10:03 ET | 200 | 14.945 |
| 10:06 ET | 1438 | 14.96 |
| 10:08 ET | 200 | 14.99 |
| 10:10 ET | 1912 | 14.965 |
| 10:12 ET | 600 | 15.05 |
| 10:14 ET | 100 | 15.05 |
| 10:15 ET | 200 | 15.05 |
| 10:17 ET | 349 | 15.09 |
| 10:19 ET | 700 | 15.07 |
| 10:21 ET | 1059 | 15.03 |
| 10:24 ET | 300 | 15.05 |
| 10:26 ET | 600 | 14.99 |
| 10:28 ET | 1268 | 14.91 |
| 10:30 ET | 286 | 14.84 |
| 10:32 ET | 100 | 14.86 |
| 10:35 ET | 1114 | 14.935 |
| 10:37 ET | 100 | 14.94 |
| 10:39 ET | 700 | 14.9 |
| 10:42 ET | 1100 | 14.9 |
| 10:46 ET | 400 | 14.93 |
| 10:51 ET | 853 | 14.94 |
| 10:55 ET | 804 | 14.89 |
| 10:57 ET | 400 | 14.89 |
| 11:00 ET | 1669 | 14.88 |
| 11:02 ET | 200 | 14.88 |
| 11:08 ET | 2391 | 14.95 |
| 11:09 ET | 300 | 14.92 |
| 11:13 ET | 129 | 14.92 |
| 11:15 ET | 482 | 14.93 |
| 11:18 ET | 200 | 14.95 |
| 11:20 ET | 781 | 15.05 |
| 11:26 ET | 361 | 15.04 |
| 11:29 ET | 1087 | 15.06 |
| 11:33 ET | 200 | 15.08 |
| 11:36 ET | 764 | 15.05 |
| 11:40 ET | 545 | 15.0704 |
| 11:42 ET | 975 | 15.07 |
| 11:45 ET | 200 | 15.06 |
| 11:47 ET | 100 | 15.05 |
| 11:49 ET | 2018 | 15.03 |
| 12:00 ET | 400 | 15.03 |
| 12:02 ET | 200 | 15.02 |
| 12:03 ET | 800 | 15 |
| 12:07 ET | 600 | 14.935 |
| 12:09 ET | 445 | 14.92 |
| 12:12 ET | 500 | 14.9 |
| 12:14 ET | 200 | 14.9 |
| 12:16 ET | 413 | 14.9 |
| 12:18 ET | 100 | 14.93 |
| 12:20 ET | 400 | 14.89 |
| 12:21 ET | 300 | 14.855 |
| 12:23 ET | 100 | 14.85 |
| 12:25 ET | 868 | 14.84 |
| 12:32 ET | 200 | 14.86 |
| 12:34 ET | 945 | 14.835 |
| 12:38 ET | 200 | 14.835 |
| 12:39 ET | 909 | 14.85 |
| 12:41 ET | 905 | 14.805 |
| 12:43 ET | 724 | 14.75 |
| 12:48 ET | 581 | 14.78 |
| 12:50 ET | 100 | 14.8 |
| 12:52 ET | 377 | 14.82 |
| 12:56 ET | 100 | 14.79 |
| 01:01 ET | 801 | 14.79 |
| 01:03 ET | 400 | 14.8 |
| 01:08 ET | 100 | 14.77 |
| 01:10 ET | 100 | 14.79 |
| 01:12 ET | 200 | 14.81 |
| 01:15 ET | 106 | 14.805 |
| 01:17 ET | 519 | 14.8 |
| 01:24 ET | 200 | 14.79 |
| 01:26 ET | 1126 | 14.741 |
| 01:28 ET | 310 | 14.74 |
| 01:30 ET | 100 | 14.73 |
| 01:32 ET | 600 | 14.68 |
| 01:33 ET | 400 | 14.7 |
| 01:35 ET | 100 | 14.68 |
| 01:37 ET | 400 | 14.725 |
| 01:39 ET | 100 | 14.735 |
| 01:44 ET | 300 | 14.72 |
| 01:46 ET | 486 | 14.72 |
| 01:48 ET | 2434 | 14.69 |
| 01:51 ET | 100 | 14.69 |
| 01:53 ET | 633 | 14.665 |
| 01:57 ET | 505 | 14.74 |
| 02:02 ET | 1687 | 14.76 |
| 02:04 ET | 613 | 14.755 |
| 02:08 ET | 100 | 14.765 |
| 02:15 ET | 200 | 14.785 |
| 02:20 ET | 400 | 14.81 |
| 02:22 ET | 831 | 14.81 |
| 02:24 ET | 875 | 14.8 |
| 02:26 ET | 400 | 14.8 |
| 02:27 ET | 513 | 14.835 |
| 02:29 ET | 300 | 14.81 |
| 02:31 ET | 303 | 14.82 |
| 02:33 ET | 630 | 14.81 |
| 02:45 ET | 100 | 14.82 |
| 02:47 ET | 1206 | 14.79 |
| 02:58 ET | 1126 | 14.81 |
| 03:05 ET | 100 | 14.83 |
| 03:07 ET | 100 | 14.85 |
| 03:09 ET | 100 | 14.87 |
| 03:12 ET | 1802 | 14.87 |
| 03:14 ET | 600 | 14.9 |
| 03:16 ET | 600 | 14.91 |
| 03:18 ET | 200 | 14.93 |
| 03:20 ET | 299 | 14.95 |
| 03:21 ET | 1363 | 14.93 |
| 03:25 ET | 400 | 14.96 |
| 03:27 ET | 300 | 14.96 |
| 03:30 ET | 992 | 14.95 |
| 03:32 ET | 908 | 15.02 |
| 03:34 ET | 1541 | 15.04 |
| 03:36 ET | 3165 | 15.045 |
| 03:38 ET | 790 | 15.05 |
| 03:39 ET | 331 | 15.06 |
| 03:41 ET | 499 | 15.06 |
| 03:43 ET | 2487 | 15.04 |
| 03:45 ET | 1013 | 15.04 |
| 03:48 ET | 1228 | 15.05 |
| 03:50 ET | 1900 | 15.015 |
| 03:52 ET | 700 | 15.02 |
| 03:54 ET | 3145 | 15.02 |
| 03:56 ET | 3574 | 14.99 |
| 03:57 ET | 4020 | 14.97 |
| 03:59 ET | 70280 | 14.96 |
May 15, 2024
DJ REGENXBIO Is Maintained at Buy by HC Wainwright & Co., from 11:41AM ET on Wednesday May 15, 2024 by Dow Jones
11:41AM ET on Wednesday May 15, 2024 by Dow Jones
May 10, 2024
REGENXBIO to Participate in Upcoming Investor Conferences, from 7:05AM ET on Friday May 10, 2024 by Dow Jones
7:05AM ET on Friday May 10, 2024 by Dow Jones
May 8, 2024
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
4:05PM ET on Wednesday May 08, 2024 by Dow Jones*DJ REGENXBIO 1Q Loss/Shr $1.38 >RGNX, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
4:05PM ET on Wednesday May 08, 2024 by Dow Jones
May 1, 2024
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights, from 7:05AM ET on Wednesday May 01, 2024 by Dow Jones
7:05AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 734.9M | -2.5x | --- |
SAGE Therapeutics Inc | 708.9M | -1.4x | --- |
WAVE Life Sciences Ltd | 761.7M | -11.9x | --- |
Zymeworks Inc | 616.5M | -4.9x | --- |
Y-mAbs Therapeutics Inc | 536.2M | -24.5x | --- |
Nurix Therapeutics Inc | 899.6M | -5.9x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Allan Fox
- President, Chief Executive Officer, Director
- Kenneth Mills
- Chief Financial Officer, Executive Vice President
- Vittal Vasista
- Chief Operating Officer, Executive Vice President
- Curran Simpson
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $734.9M |
|---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.35 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 8.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
